Reference : L'etude clinique du mois. L'etude PROSPER (PROspective study of pravastatin in the el...
Scientific journals : Article
Human health sciences : Cardiovascular & respiratory systems
Human health sciences : Pharmacy, pharmacology & toxicology
http://hdl.handle.net/2268/10616
L'etude clinique du mois. L'etude PROSPER (PROspective study of pravastatin in the elderly at risk).
French
[en] The PROSPER Study (PROspective study of pravastatin in the elderly at risk)
Kulbertus, Henri mailto [Université de Liège - ULg > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine) >]
Scheen, André mailto [Université de Liège - ULg > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
2002
Revue Médicale de Liège
57
12
809-13
Yes (verified by ORBi)
0370-629X
Belgium
[en] Aged ; Aged, 80 and over ; Anticholesteremic Agents/therapeutic use ; Female ; Humans ; Hypercholesterolemia/drug therapy ; Male ; Pravastatin/therapeutic use ; Risk Factors
[en] Statins reduce coronary and cerebrovascular mortality and morbidity in middle-aged individuals. Until recently, their efficacy and safety in elderly people had not yet been firmly established. PROSPER was a controlled, randomised study involving 2,804 men and 3,000 women aged 70-82, with a history of, or risk factors for cardiovascular disease. Their baseline cholesterol level was 135-350 mg/dl; they were randomised to either 40 mg pravastatin per day, or matching placebo. Average follow-up was 3.2 years. The primary endpoint was a composite of coronary death, non-fatal myocardial infarction, and fatal or non-fatal stroke. Pravastatin lowered LDL-cholesterol (-34%), and reduced the incidence of the primary endpoint (-15%; CI 95%: 3-26%; p = 0.014). Coronary death and non-fatal myocardial infarction risk was also reduced (-19%; p = 0.006), and mortality from coronary disease fell by 24% (p = 0.043). The risk for stroke, however, was unaffected (p = 0.8), whereas the incidence of transient ischemic attacks was reduced by 25%, which was (marginally) insignificant (p = 0.051). Pravastatin had no effect on cognitive functions or incapacity. New cancers were more frequent amongst pravastatin-treated individuals (+25%; p = 0.020). However incorporation of this new data in a meta-analysis of all pravastatin and all statin trials revealed no overall increase of cancer risk.
Researchers ; Professionals ; Students
http://hdl.handle.net/2268/10616
http://www.rmlg.ulg.ac.be

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
200212_12.pdfNo commentaryPublisher postprint441.54 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.